⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRNX News
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
globenewswire.com
CRNX
Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer
globenewswire.com
CRNX
Form 8-K
sec.gov
CRNX
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
globenewswire.com
CRNX
Crinetics Pharmaceuticals Solicita Autorização de Comercialização de Palsonify™ (Paltusotina) no Brasil para Tratamento de Acromegalia
globenewswire.com
CRNX
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
globenewswire.com
CRNX
Form 8-K
sec.gov
CRNX
Form 8-K
sec.gov
CRNX
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
globenewswire.com
CRNX
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
globenewswire.com
FHTX
CRNX
RIGL